Circulation, Vol 84, 708-711, Copyright © 1991 by American Heart Association
PM Ridker, JE Manson, JE Buring, SZ Goldhaber and CH Hennekens
BACKGROUND. The influence of prophylactic low-dose aspirin on the clinical
characteristics of subsequent nonfatal myocardial infarction was examined
in the Physicians' Health Study, a randomized, double- blind
placebo-controlled trial of alternate-day aspirin (325 mg) among 22,071 US
male physicians. METHODS AND RESULTS. During 60.2 months of follow-up, 342
incident cases of nonfatal myocardial infarction were confirmed (95.2% of
all reports): 129 on aspirin and 213 on placebo (p less than 0.00001).
Despite this statistically extreme reduction in occurrence of a first
nonfatal infarction attributable to aspirin, there were no significant
differences in the size, location, electrocardiographic features, or
postinfarction left ventricular ejection fraction between the aspirin and
placebo groups. Furthermore, among those undergoing angiography, there were
no differences in the distribution or number of coronary vessels
obstructed. CONCLUSIONS. These data indicate that chronic platelet
inhibition with alternate-day aspirin therapy reduces the risk of a first
myocardial infarction but does not appear to have a significant effect on
the clinical characteristics of events that are survived. This finding may
result from a direct effect of aspirin or from an aspirin-induced shift in
infarction severity. Regardless of mechanism, these clinical observations
suggest that treatment decisions for acute infarction patients should be
made independently of a history of aspirin use.
ARTICLES
Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy
Division of Cardiology, Brigham and Women's Hospital, Brookline, MA 02215.
This article has been cited by other articles:
![]() |
E. L. Portnay, J. M. Foody, S. S. Rathore, Y. Wang, F. A. Masoudi, J. P. Curtis, and H. M. Krumholz Prior Aspirin Use and Outcomes in Elderly Patients Hospitalized With Acute Myocardial Infarction J. Am. Coll. Cardiol., September 20, 2005; 46(6): 967 - 974. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wilterdink, B. Bendixen, H. P. Adams Jr, R. F. Woolson, W. R. Clarke, and M. D. Hansen Effect of Prior Aspirin Use on Stroke Severity in the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Stroke, December 1, 2001; 32(12): 2836 - 2840. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Frederick, O. D. Suleymanov, J. A. Szalony, B. B. Taite, A. K. Salyers, L. W. King, L. P. Feigen, and N. S. Nicholson Protective Effect of Oral Xemilofiban in Arterial Thrombosis in Dogs : Increased Activity in Combination With Aspirin Circulation, August 25, 1998; 98(8): 813 - 820. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Weiss, P. F. Bray, M. Tayback, S. P. Schulman, T. S. Kickler, L. C. Becker, J. L. Weiss, G. Gerstenblith, and P. J. Goldschmidt-Clermont A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis N. Engl. J. Med., April 25, 1996; 334(17): 1090 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Garcia-Dorado, P. Theroux, P. Tornos, A. Sambola, J. Oliveras, M. Santos, and J. S. Soler Previous Aspirin Use May Attenuate the Severity of the Manifestation of Acute Ischemic Syndromes Circulation, October 1, 1995; 92(7): 1743 - 1748. [Abstract] [Full Text] |
||||
![]() |
N. F. Col, J. Yarzebski, J. M. Gore, J. S. Alpert, and R. J. Goldberg Does Aspirin Consumption Affect the Presentation or Severity of Acute Myocardial Infarction? Arch Intern Med, July 10, 1995; 155(13): 1386 - 1389. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |